Radiation and immunotherapy combo shows promise in shrinking breast tumors before surgery
NCT ID NCT04454528
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tests whether adding a single dose of radiation to the immunotherapy drug pembrolizumab before surgery can shrink tumors in people with early-stage breast cancer. About 27 participants will receive the combination, and doctors will measure tumor shrinkage and immune cell activity. The goal is to see if this approach is safe and effective enough to delay or reduce the need for more extensive surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.